73 results on '"Perakakis, Nikolaos"'
Search Results
2. Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS)
3. Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases
4. Cross-Talk of NADPH Oxidases and Inflammation in Obesity
5. Liver fat as risk factor of hepatic and cardiometabolic diseases
6. vPIF-1 is an insulin-like antiferroptotic viral peptide
7. Activation of beta-adrenergic receptor signaling prevents glucocorticoid-induced obesity and adipose tissue dysfunction in male mice
8. Plasma proteomic profiles in prediabetes reversing to normoglycemia or progressing to diabetes in a year – a cross-sectional and prospective analysis
9. Biomarker systemischer Inflammation und langfristige Integrität der Mikrovaskulatur nach gewichtsabhängiger Prädiabetes-Remission
10. Circulating levels of gastrointestinal hormones in prediabetes reversing to normoglycemia or progressing to diabetes in a year – a cross-sectional and prospective analysis
11. Einfluss des vorherigen Gestationsdiabetes auf kardiometabolische Risikoparameter bei Patientinnen mit neu-manifestiertem Typ-2-Diabetes – eine Fall-Kontroll-Studie innerhalb der
12. Entzündungsmediatoren in neuen Clustern von Individuen mit erhöhtem Diabetesrisiko
13. C-Peptid-Glukose Ratio als Marker für zukünftige Insulinbehandlung und Glykämieverlauf bei neu diagnostiziertem Diabetes mellitus Typ 2
14. SARS-CoV-2 infection and its effects on the endocrine system
15. Circulating levels of gastrointestinal hormones in prediabetes reversing to normoglycemia or progressing to diabetesin a year– a cross-sectional and prospective analysis
16. Präzisionstherapie bei Diabetes mellitus Typ 2
17. Loci for insulin processing and secretion provide insight into type 2 diabetes risk
18. PCSK9 inhibition and cholesterol homeostasis in insulin producing β-cells
19. PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic doses
20. Circulating levels of five proglucagon-derived peptides in response to intravenous or oral glucose or lipids and to a mixed-meal in subjects with normal weight, overweight, and obesity
21. The Role of Endocrine and Metabolic System in COVID-19 Disease – The Transcampus Experience and Review of Evidence From International Collaborating Groups
22. The Potential of Electrical Stimulation and Smart Textiles for Patients with Diabetes Mellitus
23. Strategie zur strukturierten interdisziplinären Zusammenarbeit für Versorgung der Patienten mit Diabetes in Praxis und Klinik
24. Liver, NAFLD and COVID-19
25. Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial
26. The interface of COVID-19, diabetes, and depression
27. Sexual dimorphism in COVID-19: potential clinical and public health implications
28. Management von Diabetespatienten in der COVID-19-Pandemie
29. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH
30. Branched-Chain Amino Acids in relation to food preferences and insulin resistance in obese subjects consuming walnuts: A cross-over, randomized, double-blind, placebo-controlled inpatient physiology study
31. Both Elafibranor and Liraglutide Improve NAFLD / NASH but Affect Differentially the Hepatic Lipidome and Metabolome in a Diet-Induced Obese and Biopsy-Confirmed Mouse Model of NASH
32. Elafibranor and liraglutide improve differentially liver health and metabolism in a mouse model of non‐alcoholic steatohepatitis
33. Leptin in Leanness and Obesity
34. Fasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of reward‐ and attention‐related brain centres in response to visual food cues in adults with obesity: A cross‐sectional functional MRI study
35. Circulating profile of Activin-Follistatin-Inhibin Axis in women with hypothalamic amenorrhea in response to leptin treatment
36. Leptin alters energy intake and fat mass but not energy expenditure in lean subjects
37. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease
38. Quantifying Fibrinogen-Dependent Aggregation of Red Blood Cells in Type 2 Diabetes Mellitus
39. The Selective Peroxisome Proliferator‐Activated Receptor Gamma Modulator CHS‐131 Improves Liver Histopathology and Metabolism in a Mouse Model of Obesity and Nonalcoholic Steatohepatitis
40. The Role of Glicentin and Oxyntomodulin in Human Metabolism: New Evidence and New Directions
41. Sex specific effect of ATPase inhibitory factor 1 on body weight: studies in high fat diet induced obese mice and genetic association studies in humans
42. Metabolic regulation of activins in healthy individuals and in obese patients undergoing bariatric surgery
43. Circulating levels of gastrointestinal hormones in response to the most common types of bariatric surgery and predictive value for weight loss over one year: Evidence from two independent trials
44. Non-invasive diagnosis of non-alcoholic steatohepatitis and fibrosis with the use of omics and supervised learning: A proof of concept study
45. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD
46. Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial
47. Clinical Impact of the TCF7L2 Gene rs7903146 Type 2 Diabetes Mellitus Risk Polymorphism in Women with Gestational Diabetes Mellitus: Impaired Glycemic Control and Increased Need of Insulin Therapy
48. Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Ex quo et quo vadimus?
49. Circulating levels of the components of the GH/IGF-1/IGFBPs axis total and intact IGF-binding proteins (IGFBP) 3 and IGFBP 4 and total IGFBP 5, as well as PAPPA, PAPPA2 and Stanniocalcin-2 levels are not altered in response to energy deprivation and/or metreleptin administration in humans
50. Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.